Reporting tumor molecular heterogeneity in histopathological diagnosis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Mafficini, Andrea ^a   Amato, Eliana ^a   Fassan, Matteo ^a   Simbolo, Michele ^a   Antonello, Davide ^a,b   Vicentini, Caterina ^a   Scardoni, Maria ^a   Bersani, Samantha ^a   Gottardi, Marisa ^a   Rusev, Borislav ^a   Malpeli, Giorgio ^a,b   Corbo, Vincenzo ^a   Barbi, Stefano ^a   Sikora, Katarzyna O ^a   Lawlor, Rita T ^a   Tortora, Giampaolo ^b   Scarpa, Aldo ^a  

^a University and Hospital Trust of Verona   (Italy)

^b Department of Surgery University and Hospital Trust of Verona ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SMAD4 PROTEIN; B RAF KINASE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ANTIBODY LABELING; ARTICLE; BILE DUCT CARCINOMA; BRAF GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DNA DEGRADATION; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PROCEDURES; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KRAS GENE; LIMIT OF DETECTION; LIVER CELL CARCINOMA; MORPHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; PANCREAS ADENOCARCINOMA; PIK3CA GENE; SEQUENCE ALIGNMENT; STOMACH CARCINOMA; TARGETED MULTIGENE NEXT GENERATION SEQUENCING; TP53 GENE; VATER PAPILLA CARCINOMA; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; TISSUE FIXATION;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TISSUE FIXATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930026320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104979     Document Type: Article

References (37)

1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
2. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
3. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, et al. (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29: 1400-1407.
4. Balschun K, Haag J, Wenke AK, von Schonfels W, Schwarz NT, et al. (2011) KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn 13: 436-445.
5. Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, et al. (2012) Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med 10: 87.
6. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15: 234-247.
7. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, et al. (2013) Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol In Press.
8. Sorio C, Moore PS, Ennas MG, Tecchio C, Bonora A, et al. (2004) A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch 444: 269-277. (Pubitemid 38446440)
9. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, et al. (2014) Next- Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. J Clin Oncol.
10. Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, et al. (2013) DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One 8: e62692.
11. Zamo A, Bertolaso A, van Raaij AW, Mancini F, Scardoni M, et al. (2012) Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. J Mol Diagn 14: 30-37.
12. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, et al. (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6: 80-92.
13. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26.
14. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, et al. (2013) Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 8: e80478.
15. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, et al. (2013) Highthroughput mutation profiling identifies novel molecular dysregulation in highgrade intraepithelial neoplasia and early gastric cancers. Gastric Cancer.
16. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, et al. (2010) The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 29: 32.
17. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, et al. (2002) Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 160: 1361-1369. (Pubitemid 34411640)
18. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-950.
19. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
20. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
21. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
22. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
23. Jorgensen JT (2013) A changing landscape for companion diagnostics. Expert Rev Mol Diagn 13: 667-669.
24. Ow TJ, Sandulache VC, Skinner HD, Myers JN (2013) Integration of cancer genomics with treatment selection: From the genome to predictive biomarkers. Cancer.
25. Rivenbark AG, O'Connor SM, Coleman WB (2013) Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J - Pathol 183: 1113-1124.
26. Amato E, Molin MD, Mafficini A, Yu J, Malleo G, et al. (2014) Targeted nextgeneration sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol.
27. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45: 1470-1473.
28. Kerick M, Isau M, Timmermann B, Sultmann H, Herwig R, et al. (2011) Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 4: 68.
29. Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, et al. (2009) Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One 4: e5548.
30. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, et al. (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 43: 1552-1558.
31. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, et al. (2012) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangio-carcinomas and share hypermethylation targets with glioblastomas. Oncogene.
32. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
33. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44: 570-574.
34. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: 1127-1133.
35. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, et al. (2012) Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 30: 434-439.
36. Liu L, Li Y, Li S, Hu N, He Y, et al. (2012) Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012: 251364.
37. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, et al. (2012) A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13: 341.